Drugmakers Excluded from White House Pricing Pacts Seek Their Own Agreements
Several pharmaceutical firms that were not among those receiving White House directive letters to cut U.S. drug prices are pursuing alternative arrangements with federal officials. Industry sources say companies are contacting administration and CMS officials to strike deals that could shield them from potential tariffs and new Medicare pilot progr…